Geron Corporation
GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of lowā¦ read more
Healthcare
Biotechnology
29 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.07
Price-0.93%
-$0.01
1Y
Price
Market Cap
$682.678m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-15.4%
EBITDA Margin-33.4%
Net Profit Margin-56.2%
Free Cash Flow MarginRevenue
$164.447m
+113.6%
1y CAGR+10813.4%
3y CAGR+8095.8%
5y CAGREarnings
-$88.009m
+49.6%
1y CAGR+8.1%
3y CAGR+1.9%
5y CAGREPS
-$0.13
+51.8%
1y CAGR+27.0%
3y CAGR+20.3%
5y CAGRBook Value
$259.531m
$555.198m
Assets$295.667m
Liabilities$121.843m
DebtDebt to Assets
22.0%
-1.9x
Debt to EBITDAFree Cash Flow
-$178.278m
+18.7%
1y CAGR-14.4%
3y CAGR-19.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company